文献速递外周动脉疾病

年龄与BEST-CLI试验中血运重建结局关系的样条模型分析

Relationship between age and the comparative outcomes of revascularization procedures in the BEST-CLI trial: A spline model analysis.
PubMed 文献 · J Vasc Surg · 2026-02-02

基于BEST-CLI试验1780例慢性肢体威胁性缺血患者,用限制性立方样条分析年龄对开放手术与腔内治疗结局的效应修饰。队列1中单段大隐静脉旁路在72岁前MALE/死亡风险优于腔内治疗,截肢风险在约57岁前更低,MALE风险至83岁前持续更低;队列2替代导管旁路与腔内治疗无年龄差异。

要点

  • 单段大隐静脉旁路在72岁前MALE/死亡优于腔内治疗,此后无显著差异
  • 单段大隐静脉旁路截肢风险在约57岁前低于腔内治疗,之后无差异
  • 替代导管旁路时年龄不修饰血运重建结局,两种策略无年龄偏好

核心结论

  • 单段大隐静脉旁路在72岁前MALE无生存优于腔内治疗,之后两种策略结局无显著差异。
  • 腔内治疗在83岁前MALE风险显著更高,截肢风险在约57岁前也更高。
  • 使用替代导管旁路时,年龄不修饰血运重建结局或生存。

研究设计与样本

  • BEST-CLI试验数据集回顾性分析,纳入所有接受开放旁路或腔内治疗的患者。
  • 共1780例,平均年龄67.2±9.7岁,范围27.9-94.1岁。
  • 年龄作为连续变量,用限制性立方样条分析其对手术类型结局的效应修饰。
  • 队列1为单段大隐静脉旁路对比腔内治疗,队列2为替代导管旁路对比腔内治疗。
  • 每个队列针对大截肢、全因死亡、MALE和MALE/死亡生成4个样条模型。

主要发现

  • 队列1中MALE/死亡样条模型显示单段大隐静脉旁路在所有年龄风险比均较低,但风险比置信区间上限在72岁时接近1.0。
  • 死亡风险未发现年龄拐点。
  • 截肢风险在约57岁前单段大隐静脉旁路低于腔内治疗,之后两种方式无差异。
  • MALE风险在83岁前单段大隐静脉旁路持续较低。
  • 队列2中年龄不是血运重建结局或生存的效应修饰因素。

关键数值与推荐

  • MALE定义为踝以上截肢或重大再干预。
  • 主要截肢定义为踝以上截肢。
  • MALE/死亡风险比置信区间上限在72岁时接近1.0。
  • 截肢风险差异的年龄拐点约为57岁。
  • MALE风险差异持续至83岁。

临床怎么用

  • 对CLTI患者选择血运重建方式时,可参考年龄:单段大隐静脉旁路在72岁前可能优于腔内治疗。
  • 使用替代导管旁路时,年龄不应作为选择开放或腔内治疗的依据。
  • 对高龄患者需个体化决策,因72岁后两种策略MALE/死亡无显著差异。

局限性

  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age remains an important factor in decision-making and operative outcomes in patients with chronic limb-threatening ischemia (CLTI). Prior studies have used arbitrary age categories. Our aim is to identify an evidence-based age cutoff to differentiate patient outcomes between open and endovascular therapy (ET) in Best Endovascular vs Best Surgical Therapy in Patients with CLTI. METHODS: The Best Endovascular vs Best Surgical Therapy in Patients with CLTI trial dataset was queried to include all patients who underwent open surgical bypass or ET. Patient age on the day of the index revascularization was identified as a continuous variable. Restricted cubic splines were generated to examine the moderating effect of age on the outcomes of procedure type in cohort 1 (bypass with single-segment saphenous vein [SSGSV] vs ET) and cohort 2 (bypass with an alternative conduit vs ET). Four separate spline models for each cohort were generated corresponding to our outcomes of interest: major amputation (above ankle), all-cause mortality, major adverse limb events (MALE defined as above-ankle amputation or major reintervention), and MALE/death. RESULTS: Our study included 1780 patients with a mean age of 67.2 ± 9.7 years (range, 27.9-94.1 years). In cohort 1, the MALE/death spline model showed a lower hazard for SSGSV compared with ET across all ages; however, the upper limit of the hazard ratio confidence interval approaches 1.0 at age 72. There was no age inflection point identified with regard to mortality. Amputation risk was lower with SSGSV compared with ET up to around the age of 57, beyond which there was no difference between the two treatment modalities. Furthermore, the risk of MALE was consistently lower with SSGSV for patients up to age 83. In contrast, in cohort 2, age was not found to be an effect modifier in revascularization outcomes or survival among patients undergoing bypass with an alternative conduit compared with ET. CONCLUSIONS: In this study, we confirmed that bypass with SSGSV was associated with superior MALE-free survival compared with ET up to the age of 72, beyond which there was no significant difference in outcomes between the two strategies. MALE was significantly higher for ET for patients up to age 83. Patient age was not found to favor one revascularization method over the other if the bypass was performed using an alternative conduit. Further studies are needed to compare the effectiveness of revascularization strategies among older patients with CLTI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Malas MB, Hamouda M, Farber A, et al. Relationship between age and the comparative outcomes of revascularization procedures in the BEST-CLI trial: A spline model analysis. J Vasc Surg. 2026. PMID: 41638370. doi:10.1016/j.jvs.2026.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。